Share-based Payment Arrangement, Expense of Ultragenyx Pharmaceutical Inc. from 31 Dec 2012 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Ultragenyx Pharmaceutical Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2012 to 31 Dec 2025.
  • Ultragenyx Pharmaceutical Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $37,465,000, a 6.6% decline year-over-year.
  • Ultragenyx Pharmaceutical Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $153,000,000, a 3.2% decline year-over-year.
  • Ultragenyx Pharmaceutical Inc. annual Share-based Payment Arrangement, Expense for 2025 was $153,000,000, a 3.2% decline from 2024.
  • Ultragenyx Pharmaceutical Inc. annual Share-based Payment Arrangement, Expense for 2024 was $158,000,000, a 17% increase from 2023.
  • Ultragenyx Pharmaceutical Inc. annual Share-based Payment Arrangement, Expense for 2023 was $135,000,000, a 3.6% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Ultragenyx Pharmaceutical Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $153,000,000 $37,465,000 -$2,669,000 -6.6% 01 Oct 2025 31 Dec 2025 10-K 18 Feb 2026 2025 FY
Q3 2025 $155,669,000 $37,010,000 -$4,559,000 -11% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $160,228,000 $38,615,000 -$748,000 -1.9% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $160,976,000 $39,910,000 +$2,976,000 +8.1% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $158,000,000 $40,134,000 +$6,603,000 +20% 01 Oct 2024 31 Dec 2024 10-K 18 Feb 2026 2025 FY
Q3 2024 $151,397,000 $41,569,000 +$6,692,000 +19% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $144,705,000 $39,363,000 +$4,710,000 +14% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $139,995,000 $36,934,000 +$4,995,000 +16% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $135,000,000 $33,531,000 +$4,176,000 +14% 01 Oct 2023 31 Dec 2023 10-K 18 Feb 2026 2025 FY
Q3 2023 $130,824,000 $34,877,000 -$884,000 -2.5% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $131,708,000 $34,653,000 -$1,212,000 -3.4% 01 Apr 2023 30 Jun 2023 10-Q 02 Aug 2024 2024 Q2
Q1 2023 $132,920,000 $31,939,000 +$2,552,000 +8.7% 01 Jan 2023 31 Mar 2023 10-Q 03 May 2024 2024 Q1
Q4 2022 $130,368,000 $29,355,000 +$2,806,000 +11% 01 Oct 2022 31 Dec 2022 10-K 19 Feb 2025 2024 FY
Q3 2022 $127,562,000 $35,761,000 +$8,771,000 +32% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $118,791,000 $35,865,000 +$8,723,000 +32% 01 Apr 2022 30 Jun 2022 10-Q 04 Aug 2023 2023 Q2
Q1 2022 $110,068,000 $29,387,000 +$5,089,000 +21% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2023 2023 Q1
Q4 2021 $104,979,000 $26,549,000 +$3,736,000 +16% 01 Oct 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
Q3 2021 $101,243,000 $26,990,000 +$6,649,000 +33% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $94,594,000 $27,142,000 +$4,733,000 +21% 01 Apr 2021 30 Jun 2021 10-Q 29 Jul 2022 2022 Q2
Q1 2021 $89,861,000 $24,298,000 +$4,126,000 +20% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 $85,735,000 $22,813,000 +$3,153,000 +16% 01 Oct 2020 31 Dec 2020 10-K 17 Feb 2023 2022 FY
Q3 2020 $82,582,000 $20,341,000 +$434,000 +2.2% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $82,148,000 $22,409,000 +$202,000 +0.91% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $81,946,000 $20,172,000 -$49,000 -0.24% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $81,995,000 $19,660,000 -$1,420,000 -6.7% 01 Oct 2019 31 Dec 2019 10-K 15 Feb 2022 2021 FY
Q3 2019 $83,415,000 $19,907,000 -$760,000 -3.7% 01 Jul 2019 30 Sep 2019 10-Q 27 Oct 2020 2020 Q3
Q2 2019 $84,175,000 $22,207,000 +$2,644,000 +14% 01 Apr 2019 30 Jun 2019 10-Q 30 Jul 2020 2020 Q2
Q1 2019 $81,531,000 $20,221,000 +$1,424,000 +7.6% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $80,107,000 $21,080,000 +$1,539,000 +7.9% 01 Oct 2018 31 Dec 2018 10-K 12 Feb 2021 2020 FY
Q3 2018 $78,568,000 $20,667,000 +$3,487,000 +20% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $75,081,000 $19,563,000 +$2,769,000 +16% 01 Apr 2018 30 Jun 2018 10-Q 02 Aug 2019 2019 Q2
Q1 2018 $72,312,000 $18,797,000 +$4,298,000 +30% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $68,014,000 $19,541,000 +$6,003,000 +44% 01 Oct 2017 31 Dec 2017 10-K 14 Feb 2020 2019 FY
Q3 2017 $62,011,000 $17,180,000 +$3,486,000 +25% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $58,525,000 $16,794,000 +$5,934,000 +55% 01 Apr 2017 30 Jun 2017 10-Q 03 Aug 2018 2018 Q2
Q1 2017 $52,591,000 $14,499,000 +$4,282,000 +42% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $48,309,000 $13,538,000 +$4,049,000 +43% 01 Oct 2016 31 Dec 2016 10-K 20 Feb 2019 2018 FY
Q3 2016 $44,260,000 $13,694,000 +$5,798,000 +73% 01 Jul 2016 30 Sep 2016 10-Q 03 Nov 2017 2017 Q3
Q2 2016 $38,462,000 $10,860,000 +$5,769,000 +113% 01 Apr 2016 30 Jun 2016 10-Q 28 Jul 2017 2017 Q2
Q1 2016 $32,693,000 $10,217,000 +$7,809,000 +324% 01 Jan 2016 31 Mar 2016 10-Q 05 May 2017 2017 Q1
Q4 2015 $24,884,000 $9,489,000 +$7,488,000 +374% 01 Oct 2015 31 Dec 2015 10-K 21 Feb 2018 2017 FY
Q3 2015 $17,396,000 $7,896,000 +$6,244,000 +378% 01 Jul 2015 30 Sep 2015 10-Q 08 Nov 2016 2016 Q3
Q2 2015 $11,152,000 $5,091,000 +$4,145,000 +438% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 $7,007,000 $2,408,000 +$1,613,000 +203% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q4 2014 $5,394,000 $2,001,000 +$1,791,000 +853% 01 Oct 2014 31 Dec 2014 10-K 17 Feb 2017 2016 FY
Q3 2014 $3,603,000 $1,652,000 +$1,581,000 +2227% 01 Jul 2014 30 Sep 2014 10-Q 10 Nov 2015 2015 Q3
Q2 2014 $2,022,000 $946,000 +$761,000 +411% 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015 2015 Q2
Q1 2014 $1,261,000 $795,000 +$604,000 +316% 01 Jan 2014 31 Mar 2014 10-Q 12 May 2015 2015 Q1
Q4 2013 $657,000 $210,000 01 Oct 2013 31 Dec 2013 10-K 26 Feb 2016 2015 FY
Q3 2013 $71,000 01 Jul 2013 30 Sep 2013 10-Q 10 Nov 2014 2014 Q3
Q2 2013 $185,000 01 Apr 2013 30 Jun 2013 10-Q 11 Aug 2014 2014 Q2
Q1 2013 $191,000 01 Jan 2013 31 Mar 2013 10-Q 12 May 2014 2014 Q1

Ultragenyx Pharmaceutical Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $153,000,000 -$5,000,000 -3.2% 01 Jan 2025 31 Dec 2025 10-K 18 Feb 2026 2025 FY
2024 $158,000,000 +$23,000,000 +17% 01 Jan 2024 31 Dec 2024 10-K 18 Feb 2026 2025 FY
2023 $135,000,000 +$4,632,000 +3.6% 01 Jan 2023 31 Dec 2023 10-K 18 Feb 2026 2025 FY
2022 $130,368,000 +$25,389,000 +24% 01 Jan 2022 31 Dec 2022 10-K 19 Feb 2025 2024 FY
2021 $104,979,000 +$19,244,000 +22% 01 Jan 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
2020 $85,735,000 +$3,740,000 +4.6% 01 Jan 2020 31 Dec 2020 10-K 17 Feb 2023 2022 FY
2019 $81,995,000 +$1,888,000 +2.4% 01 Jan 2019 31 Dec 2019 10-K 15 Feb 2022 2021 FY
2018 $80,107,000 +$12,093,000 +18% 01 Jan 2018 31 Dec 2018 10-K 12 Feb 2021 2020 FY
2017 $68,014,000 +$19,705,000 +41% 01 Jan 2017 31 Dec 2017 10-K 14 Feb 2020 2019 FY
2016 $48,309,000 +$23,425,000 +94% 01 Jan 2016 31 Dec 2016 10-K 20 Feb 2019 2018 FY
2015 $24,884,000 +$19,490,000 +361% 01 Jan 2015 31 Dec 2015 10-K 21 Feb 2018 2017 FY
2014 $5,394,000 +$4,737,000 +721% 01 Jan 2014 31 Dec 2014 10-K 17 Feb 2017 2016 FY
2013 $657,000 -$234,000 -26% 01 Jan 2013 31 Dec 2013 10-K 26 Feb 2016 2015 FY
2012 $891,000 01 Jan 2012 31 Dec 2012 10-K 27 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.